Evolus (NASDAQ:EOLS) Stock Price Up 15.3% – What’s Next?

Evolus, Inc. (NASDAQ:EOLS)’s stock price shot up 15.3% during trading on Thursday . The stock traded as high as $14.85 and last traded at $16.44. 203,784 shares changed hands during mid-day trading, a decline of 77% from the average session volume of 868,460 shares. The stock had previously closed at $14.26.

Analysts Set New Price Targets

A number of equities analysts recently commented on EOLS shares. Barclays raised their price objective on shares of Evolus from $20.00 to $22.00 and gave the stock an “overweight” rating in a research note on Monday, January 27th. HC Wainwright reissued a “buy” rating and set a $27.00 price target on shares of Evolus in a research report on Friday. Finally, Needham & Company LLC restated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research report on Tuesday, January 21st.

Evolus Stock Performance

The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58. The firm has a market capitalization of $933.34 million, a PE ratio of -16.20 and a beta of 1.33. The firm’s fifty day moving average price is $12.08 and its 200 day moving average price is $13.98.

Hedge Funds Weigh In On Evolus

A number of hedge funds have recently added to or reduced their stakes in EOLS. China Universal Asset Management Co. Ltd. grew its position in Evolus by 10.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 13,426 shares of the company’s stock worth $148,000 after acquiring an additional 1,291 shares in the last quarter. Rhumbline Advisers lifted its stake in shares of Evolus by 2.2% in the 4th quarter. Rhumbline Advisers now owns 80,149 shares of the company’s stock valued at $885,000 after purchasing an additional 1,762 shares during the last quarter. Tradition Wealth Management LLC boosted its holdings in Evolus by 18.2% in the fourth quarter. Tradition Wealth Management LLC now owns 13,000 shares of the company’s stock worth $144,000 after purchasing an additional 2,000 shares in the last quarter. MetLife Investment Management LLC increased its position in Evolus by 6.3% during the fourth quarter. MetLife Investment Management LLC now owns 34,272 shares of the company’s stock worth $378,000 after buying an additional 2,044 shares during the last quarter. Finally, Teacher Retirement System of Texas raised its holdings in Evolus by 19.5% during the fourth quarter. Teacher Retirement System of Texas now owns 14,084 shares of the company’s stock valued at $155,000 after buying an additional 2,302 shares in the last quarter. Institutional investors and hedge funds own 90.69% of the company’s stock.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.